Table 2.
Weight (g) | Tracer uptake in %ID/g | SUL (SUV LBM) | ||||
---|---|---|---|---|---|---|
FFT, n = 92 | ||||||
Mean | 0.62 | 0.00022 | 0.16 | |||
± SD | ± 0.96 | ± 0.00064 | ± 0.37 | |||
Median | 0.16 | 0.0 | 0.010 | |||
Range | 0.01–4.2 | 0.0–0.003 | 0.0–2.0 |
p value Mann–Whitney U test | p value Mann–Whitney U test | p value Mann–Whitney U test | ||||
---|---|---|---|---|---|---|
LN samples*, n = 252 | ||||||
Mean | 0.63 | 0.00059 | 0.37 | |||
± SD | ± 1.1 | ± 0.00075 | ± 0.40 | |||
Median | 0.18 | 0.0 | 0.26 | |||
Range | 0.01–7.8 | 0.0–0.0040 | 0.0–2.2 | |||
LNM samples*, n = 154 | < 0.0001 (LN vs LNM) | < 0.0001 (LN vs LNM) | < 0.0001 (LN vs LNM) | |||
Mean | 0.84 | 0.019 | 12.0 | |||
± SD | ± 1.2 | ± 0.041 | ± 24.0 | |||
Median | 0.36 | 0.0050 | 3.5 | |||
Range | 0.01–6.0 | 0.0–0.29 | 0.0–169 |
LN lymph node, LNM lymph node metastases, FFT fibro-fatty-tissue, PCa prostate cancer
*60/498 LN-samples containing more than one LN/LNM resulting in overall 356 LN and 171 LNM (including 11 non-nodal PCa tissue)